This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Case Study
Daoxin Wang
Second Affiliated Hospital of Chongqing medical university
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Coronavirus disease 2019 (COVID-19) has become a global pandemic, affecting the lives of millions of people around the world.Although research including hydroxychloroquine, antiviral drugs and vaccines is under way, there is still no effective therapy applied for COVID-19.
Case presentation: Here, we reported five cases of severe COVID-19 patients with respiratory failure treatment with supportable care and ABO-compatible convalescent plasma (CP).All the patients’ clinical conditions, laboratory results, viral nucleic acid results, and chest CT images, were improved. Meanwhile, all the patients recovered and no severe adverse reactions were found. We also followed up the antibody levels of some patients within 2 months after onset, but our study did not show the inherent relationship between CP treatment and changes in antibody levels due to small samples.
Conclusions: Although short of evidence of randomized controlled trials, convalescent plasma therapy probably was a potentially safe and effective treatment for COVID-19.
Keywords
COVID-19, Convalescent plasma (CP) therapy, Viral nucleic acid, Oxygenation index (OI), Chest CT image, IgG, IgM
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 09 Jul, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
Learn more about our company.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Case Study
Daoxin Wang
Second Affiliated Hospital of Chongqing medical university
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 09 Jul, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Coronavirus disease 2019 (COVID-19) has become a global pandemic, affecting the lives of millions of people around the world.Although research including hydroxychloroquine, antiviral drugs and vaccines is under way, there is still no effective therapy applied for COVID-19.
Case presentation: Here, we reported five cases of severe COVID-19 patients with respiratory failure treatment with supportable care and ABO-compatible convalescent plasma (CP).All the patients’ clinical conditions, laboratory results, viral nucleic acid results, and chest CT images, were improved. Meanwhile, all the patients recovered and no severe adverse reactions were found. We also followed up the antibody levels of some patients within 2 months after onset, but our study did not show the inherent relationship between CP treatment and changes in antibody levels due to small samples.
Conclusions: Although short of evidence of randomized controlled trials, convalescent plasma therapy probably was a potentially safe and effective treatment for COVID-19.
Figure 1
Loading...